Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS

Trial Profile

SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms SHORT-HER
  • Most Recent Events

    • 13 Sep 2018 Primary endpoint (Overall survival rate) has not been met, according to results published in the Annals of Oncology.
    • 13 Sep 2018 Primary endpoint (Disease-free survival rate) has not been met, according to results published in the Annals of Oncology.
    • 13 Sep 2018 Results (n=1254) published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top